Research Analysts Set Expectations for MRNS FY2024 Earnings

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) – HC Wainwright raised their FY2024 EPS estimates for Marinus Pharmaceuticals in a report released on Thursday, November 14th. HC Wainwright analyst D. Tsao now forecasts that the biopharmaceutical company will post earnings of ($1.95) per share for the year, up from their previous forecast of ($2.00). HC Wainwright currently has a “Neutral” rating and a $2.00 target price on the stock. The consensus estimate for Marinus Pharmaceuticals’ current full-year earnings is ($1.93) per share. HC Wainwright also issued estimates for Marinus Pharmaceuticals’ Q1 2025 earnings at ($0.18) EPS, Q2 2025 earnings at ($0.15) EPS, Q3 2025 earnings at ($0.13) EPS, Q4 2025 earnings at $0.04 EPS, FY2025 earnings at ($0.42) EPS, FY2026 earnings at ($0.26) EPS, FY2027 earnings at $0.14 EPS and FY2028 earnings at $0.54 EPS.

Other equities analysts have also issued research reports about the stock. StockNews.com initiated coverage on shares of Marinus Pharmaceuticals in a research report on Monday. They set a “hold” rating for the company. Royal Bank of Canada dropped their price target on shares of Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating on the stock in a research note on Friday, October 25th. TD Cowen reiterated a “hold” rating on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. JMP Securities reissued a “market perform” rating on shares of Marinus Pharmaceuticals in a report on Thursday, October 24th. Finally, Truist Financial lowered shares of Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 24th. Nine research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Marinus Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $4.79.

Marinus Pharmaceuticals Price Performance

MRNS opened at $0.31 on Monday. The firm’s fifty day moving average price is $1.22 and its two-hundred day moving average price is $1.31. The company has a market capitalization of $17.00 million, a price-to-earnings ratio of -0.12 and a beta of 1.26. Marinus Pharmaceuticals has a 1 year low of $0.26 and a 1 year high of $11.26.

Institutional Investors Weigh In On Marinus Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the company. abrdn plc boosted its holdings in shares of Marinus Pharmaceuticals by 146.1% during the 3rd quarter. abrdn plc now owns 2,658,527 shares of the biopharmaceutical company’s stock valued at $4,679,000 after acquiring an additional 1,578,329 shares during the last quarter. Suvretta Capital Management LLC boosted its holdings in shares of Marinus Pharmaceuticals by 32.8% in the third quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock worth $8,930,000 after buying an additional 1,253,901 shares during the last quarter. Avoro Capital Advisors LLC raised its position in Marinus Pharmaceuticals by 31.4% in the first quarter. Avoro Capital Advisors LLC now owns 4,140,607 shares of the biopharmaceutical company’s stock worth $37,431,000 after acquiring an additional 990,607 shares during the period. GSA Capital Partners LLP lifted its position in Marinus Pharmaceuticals by 409.4% during the third quarter. GSA Capital Partners LLP now owns 1,016,634 shares of the biopharmaceutical company’s stock valued at $1,789,000 after purchasing an additional 817,050 shares in the last quarter. Finally, Acadian Asset Management LLC bought a new stake in Marinus Pharmaceuticals during the second quarter valued at about $813,000. Hedge funds and other institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.